Amgen Inc.
AMGN
Rang in Aktien
#73
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Aktienkurs
$435.12
Marktkapitalisierung
$235.24B
Veränderung (1 Tag)
2.39%
Veränderung (1 Jahr)
43.45%
Land
US
Handel Amgen Inc. (AMGN)
Kategorie
Healthcare
KGV für Amgen Inc. (AMGN)
KGV zum October 2026 TTM: 26.27
Laut den neuesten Finanzberichten und dem Aktienkurs von Amgen Inc. beträgt das aktuelle P/E-Verhältnis (TTM) 26.27. Am Ende des Jahres 2024 hatte das Unternehmen ein P/E von 34.48.
P/E-Verlaufsdaten für Amgen Inc. von 2000 bis 2026
P/E-Verhältnis am Ende jedes Jahres
| Jahr | KGV | ändert |
|---|---|---|
| 2026 (TTM) | 26.27 | 15.02% |
| 2025 | 22.84 | -33.76% |
| 2024 | 34.48 | 50.28% |
| 2023 | 22.94 | 6.37% |
| 2022 | 21.57 | -0.89% |
| 2021 | 21.76 | 17.32% |
| 2020 | 18.55 | -0.27% |
| 2019 | 18.60 | 21.32% |
| 2018 | 15.33 | -76.14% |
| 2017 | 64.23 | 353.55% |
| 2016 | 14.16 | -20.13% |
| 2015 | 17.73 | -24.35% |
| 2014 | 23.44 | 38.64% |
| 2013 | 16.91 | 9.96% |
| 2012 | 15.38 | -2.55% |
| 2011 | 15.78 | 38.52% |
| 2010 | 11.39 | -8.74% |
| 2009 | 12.48 | -15.25% |
| 2008 | 14.73 | -10.12% |
| 2007 | 16.38 | -39.83% |
| 2006 | 27.23 | 2.64% |
| 2005 | 26.53 | -23.11% |
| 2004 | 34.50 | -2.04% |
| 2003 | 35.22 | -187.92% |
| 2002 | -40.06 | -176.02% |
| 2001 | 52.70 | -8.86% |
| 2000 | 57.82 | 0.00% |
P/E-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/E Ratio | P/E Ratio-Differenz | Land |
|---|---|---|---|
| 40.53 | 54.27% |
US
|
|
| 38.50 | 46.53% |
US
|
|
| 79.88 | 204.06% |
US
|
|
| 116.96 | 345.20% |
US
|
|
| 22.25 | -15.31% |
CH
|
Wie liest man ein P/E Ratio?
Das Kurs-Gewinn-Verhältnis (P/E Ratio) misst das Verhältnis zwischen dem Aktienkurs eines Unternehmens und seinem Gewinn pro Aktie.
Ein niedriges, aber positives P/E weist auf ein Unternehmen hin, das hohe Gewinne im Verhältnis zur aktuellen Bewertung erzielt und möglicherweise unterbewertet ist. Ein Unternehmen mit einem hohen negativen (nahe 0) P/E macht hohe Verluste im Verhältnis zur Bewertung.
Unternehmen mit einem P/E über 30 oder negativ werden allgemein als "Wachstumsaktien" betrachtet, was bedeutet, dass Investoren erwarten, dass das Unternehmen in Zukunft wächst oder profitabel wird.
Unternehmen mit einem positiven P/E unter 10 gelten im Allgemeinen als "Value-Aktien", was bedeutet, dass das Unternehmen bereits sehr profitabel ist, aber in Zukunft wahrscheinlich kein starkes Wachstum aufweisen wird.